Welcome to our dedicated page for CVRx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on CVRx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company headquartered in Minneapolis, Minnesota. The company specializes in developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Its flagship product, Barostim, leverages proprietary technology to treat high blood pressure and heart failure by utilizing the body's natural blood flow regulation system.
Barostim is an implantable device that delivers electrical pulses to the baroreceptors located in the wall of the carotid artery. These pulses activate the baroreflex, which in turn restores balance to the autonomic nervous system, reducing heart failure symptoms. Barostim is FDA-approved for heart failure patients in the U.S. and has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. The device can be tailored to meet individual patient therapy needs.
The majority of CVRx's revenue is generated from the U.S. market. The company has seen significant growth, particularly in its U.S. heart failure business, which recorded nearly 120% revenue growth compared to the previous year. As of June 30, 2023, CVRx operates with 140 active implanting centers in the U.S., up from 122 as of March 31, 2023. The company's revenue for the second quarter of 2023 was $9.5 million, marking an 89% increase over the same period in 2022.
CVRx continues to expand its reach with a growing number of implanting centers and sales territories. In Europe, the company generated $1.2 million in revenue for the second quarter of 2023, a 10% increase over the previous year. Despite facing competition, CVRx remains focused on establishing and maintaining strong sales and marketing capabilities to promote the merits of Barostim.
In recent news, CVRx announced the reassignment of Barostim to a higher-paying code by the Centers for Medicare & Medicaid Services (CMS), which will facilitate increased access to the therapy by offering hospitals sufficient reimbursement. The company also reported preliminary unaudited revenue results for the fourth quarter and full year of 2023, showing continued growth. Total revenue for the fourth quarter of 2023 is expected to be between $11.2 million and $11.3 million, representing a 56-58% increase over the fourth quarter of 2022.
As CVRx looks toward the future, the company is optimistic about further expanding the adoption of Barostim. A strong foundation, exceptional leadership, and consistent execution of its strategy position CVRx well for future commercial growth. The company is actively seeking a successor for its retiring CEO, Nadim Yared, ensuring a seamless transition and continued focus on improving patients' lives.
CVRx, Inc launches its new Barostim Programmer, enhancing programming for the Barostim therapy for heart failure. Approved by the FDA, this second-generation device incorporates a modern design, upgraded cellular capabilities, and a user-friendly interface, facilitating easier programming of implantable pulse generators. CEO Nadim Yared emphasized the improvements in hardware and software, aimed at better customer support. The rollout across the U.S. market is scheduled throughout 2022.
CVRx, a medical device company, will present at the William Blair 42nd Annual Growth Stock Conference on June 6, 2022, at 3:20 pm Central Time. The presentation will be available via webcast on the company's investor relations page. CVRx is known for Barostim™, the first FDA-approved neuromodulation technology for heart failure, which delivers electrical pulses to carotid artery baroreceptors to restore autonomic balance and alleviate symptoms. Barostim has received both FDA Breakthrough Device designation and the CE Mark for heart-related conditions.
CVRx, Inc. (NASDAQ: CVRX) has received FDA approval for MR conditional labeling of its Barostim System, allowing heart failure patients with the device to safely undergo MRI scans of the head and lower extremities. This approval enhances diagnostic options for patients receiving Barostim therapy. Barostim, the first FDA-approved neuromodulation device for heart failure, helps improve symptoms by stimulating baroreceptors. In clinical studies, patients demonstrated improved walking distance, quality of life, and reduced cardiovascular events compared to a control group.
CVRx reported a 43% increase in first quarter 2022 revenue, totaling $4.1 million, driven by strong U.S. heart failure revenue growth of 133% to $2.9 million. The company achieved notable milestones, including an expansion of active implanting centers from 19 to 56 and territories from 6 to 17 year-over-year. Despite these gains, net loss widened to $10 million or $0.49 per share, and European revenue fell 18%. The outlook for 2022 remains positive, projecting total revenue between $20 million and $23 million.
CVRx announced plans to release its first quarter 2022 financial results on April 25, 2022, after market close. The company will host a conference call at 4:30 p.m. ET the same day for discussion of the results. Investors can join the call by dialing (833) 730-3980 for U.S. participants or +1 (720) 405-2140 for international callers, using the conference code 8433167. CVRx specializes in neuromodulation solutions for cardiovascular diseases, including the FDA-approved Barostim device, aimed at improving heart failure symptoms.
CVRx reported a significant 75% revenue increase for Q4 2021, reaching $3.7 million compared to Q4 2020. Key growth drivers included U.S. heart failure revenue, which soared 345% year-over-year to $2.7 million. For the full year, CVRx achieved a 115% total revenue increase to $13 million and fully repaid a $20 million loan in November 2021. The company anticipates total revenue between $20 million and $23 million for 2022, with an improved gross margin forecast of 74% to 76%.
CVRx, a commercial-stage medical device company, announced it will release its fourth quarter and full year 2021 financial results on February 15, 2022. The company will hold a conference call at 5:30 p.m. Eastern Time to discuss the results. Investors can join by dialling (833) 730-3980 for U.S. callers or +1 (720) 405-2140 internationally, referencing conference code 2879175. The FDA-approved Barostim™ device is designed to improve heart failure symptoms by stimulating the body's baroreceptors.
CVRx reported preliminary fourth quarter 2021 revenues of approximately $3.6 million to $3.7 million, a 71% to 77% increase from Q4 2020. Full year 2021 revenue is projected at $13.0 million to $13.1 million, reflecting a 113% to 116% growth from 2020. The company had 46 active implanting centers and reported cash and equivalents of $142 million. For 2022, CVRx anticipates total revenue between $20 million and $23 million with operating expenses of $55 million to $61 million. Despite challenges in Europe, the U.S. heart failure sector shows resilience.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:45 pm ET. The presentation will be available via a live audio webcast on the company’s investor relations page, with a replay accessible for 90 days. CVRx is known for its FDA-approved Barostim device that alleviates symptoms of heart failure through electrical pulses to baroreceptors, receiving both FDA Breakthrough Device designation and CE Mark approval.
CVRx, a medical device company specializing in innovative neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference. The management team's pre-recorded fireside chat is scheduled for November 22, 2021, at 10:00 a.m. ET, accessible via their investor relations page at ir.cvrx.com.
CVRx is known for Barostim™, the first FDA-approved device using neuromodulation to alleviate heart failure symptoms, receiving both the FDA Breakthrough Device designation and CE Mark for its effectiveness.
FAQ
What is the current stock price of CVRx (CVRX)?
What is the market cap of CVRx (CVRX)?
What is CVRx, Inc.?
What is Barostim?
Where is CVRx headquartered?
What recent achievements has CVRx reported?
What is the revenue projection for CVRx in the fourth quarter of 2023?
Has Barostim received regulatory approval?
What markets does CVRx primarily serve?
Who is the current CEO of CVRx?
What is the significance of the CMS reassignment for Barostim?
What is the outlook for CVRx's future growth?
